USP Issues Revised Glycerin Monograph

News
Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

The US Pharmacopeial Convention announced a revised glycerin monograph in the United States Pharmacopeia.

Rockville, MD (Mar. 17)-The US Pharmacopeial Convention announced a revised glycerin monograph in the United States Pharmacopeia (USP). The revision strengthens safety measures to prevent serious and potentially fatal health hazards associated with diethylene glycol-contaminated glycerin. Diethylene glycol is a poisonous chemical used in industrial solvents and antifreeze.

Glycerin is used as a sweetener in formulations of many pharmaceutical syrups and consumer products such as toothpaste. In May 2007, US Food and Drug Administration issued the Guidance for Industry: Testing of Glycerin for Diethylene Glycol. That guidance emphasized the importance of screening ingredients and products for the presence of diethylene glycol. FDA and USP worked together to change the current glycerin monograph. This change will require drug-product manufacturers that use glycerin-not just the glycerin manufacturer-to prove that glycerin is not present, using the USP glycerin monograph.

The revision of the USP glycerin monograph wil be effective May 15, 2008. It addresses the adulteration and contamination of glycerin with the following changes:

Revision of Identification B-In the Identification B procedure of the monograph, a gas–liquid chromatographic with flame ionization detection test will be used to confirm the presence or absence of glycerin, diethylene glycol, and ethylene glycol by a peak at the relative retention times for these compounds, respectively. When a peak is present for these impurities, the monograph will direct the user to quantify the impurities.

Replace the test “Limit of diethylene glycol and related compounds”-A new procedure is added for testing for impurities of diethylene glycol and ethylene glycol to ascertain the level at which the impurities are present. The test, “Diethylene glycol and ethylene glycol impurities,” is capable of quantifying diethylene glycol and ethylene glycol at or above the limit of quantitation (0.025%).

The revised monograph will appear in Supplement 2to USP 31–NF 26, which will be published in June 2008. 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes